Glutamate and neuropsychiatric disorders: Genetic findings and strategies Shany Edelman, Salomon Israel and Richard P. Ebstein
1
The NMDA receptor hypofunction hypothesis of schizophrenia Nuri B. Farber
31
Glutamatergic neurochemical changes in schizophrenia Guochuan Emil Tsai and David Rad
53
D-serine in the developing human central nervous system: Clinical implications Sabine A. Fuchs, Leo W.J. Klomp and Tom J. deKoning
75
The ketamine paradigm in humans: Relevance to psychotic disorders Hyun-Sang Cho, Edward Perry, Handan Gunduz-Bruce and Deepak Cyril D’Souza
99
AMPA receptor ligands: Pharmacology and therapeutic potential Donald Goff
133
mGlu2/3 receptor agonists: A new treatment approach for schizophrenia Bruce J. Kinon, Katherine M. Dale and David L. McKinzie
147
Glutamatergic neurotransmission modulation as preventive pharmacological intervention in schizophrenia Uriel Heresco-Levy
157
Future treatment approaches based upon the PCP/NMDA model of schizophrenia Daniel C. Javitt
177
Glutamatergic function in autism Craig A. Erickson, Christopher J. McDougle, Kimberly A. Stigler and David J. Posey
197
The promising role of the glutamate system in mood disorders Carlos A. Zarate Jr. and Husseini K. Manji
213
Glutamate in fear and anxiety Bernadette M. Cortese and K. Luan Phan
253
Emotional learning and glutamate: Novel applications Kimberly A. Maguschak and Kerry J. Ressler
281
